

RECEIVED

JAN 1 6 2003

TECH CENTER 1600/2900

PATENT
Attorney Docket No. EXT-036

1630

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Shuber

SERIAL NO.:

09/514.865

GROUP NO.:

1634

FILING DATE:

February 28, 2000

EXAMINER:

S. Sakelaris

TITLE:

Methods for Disease Detection

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, Washington, DC 20231 on this 13 day of January, 2003.

Thomas F. Hellenthal


Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herewith is/are:

- 1. Transmittal Form (1 page);
- 2. Fee Transmittal (1 page);
- 3. Check in the amount of \$180.00;
- 4. Supplemental Information Disclosure Statement (2 pages);
- 5. Form PTO-1449 (11 pages);
- 6. Copies of References A47-A112, B43-B111, C95-C174;
- 7. Return receipt postcard.

2562677



Application Serial Number	09/514.865	Ø ₄
Filing Date	February 28, 2000	
First Named Inventor	Shuber	ECL. SAM
Group Art Unit	1634	Colored
Examiner Name	S. Sakelaris	(\$p_
Attorney Docket No.	EXT-036	500
Patent No.	Not applicable	-
Issue Date	Not applicable	

PAIL	MAN 1 6 2003 52		Filing Date First Named Inventor			Shuber Cy Ay			
	TRANSMITTA	Group Art			1634				
	FORM		Examiner N			Sakelaris Sp			
	I OIUVI		Attorney D	ocket No.		EXT-036 33			
			Patent No.		N	Not applicable			
			Issue Date		N	lot applicable			
		E	NCLOSURES (6	check all that apply)	***				
⊠ I	ee Transmittal Form		Copy of Notic	e to File Missing		Notice of Appeal to Board			
	☑ Check Attached☐ Copy of FeeTransmittal Form		Parts of Appli Formal Drawi	cation (PTO-1553)		of Patent Appeals and Interferences Appeal Brief (in triplicate)			
	Amendment/Response		Request For C Examination (Status Inquiry			
	☐ Preliminary ☐ After Final		Transmittal			Return Receipt Postcard			
	☐ Affidavits/declaration(s) ☐ Letter to Official ☐ Draftsperson	Power of Atto (Revocation o		rney f Prior Powers)	\boxtimes	Certificate of First Class Mailing under 37 C.F.R. 1.8			
	including Drawings [Total Sheets]		Terminal Disclaimer			Certificate of Facsimile Transmission under 37 C.F.R. 1.8			
	Petition for Extension of Fime			laration and Power or Utility or Design ation		Additional Enclosure(s) (please identify below)			
\boxtimes	Supplemental Information Disclosure Statement Supplemental Form		Small Entity S	ıll Entity Statement					
	PTO-1449 Copies of IDS Citations		CD(s) for larg program	e table or computer					
	Certified Copy of Priority		Amendment A	After Allowance					
	Document(s) Sequence Listing submission Request for C Correction		of Correction (in						
COR	RESPONDENCE ADDRESS			SIGNATURE BL	0 <u>CK</u>				
Direc	Direct all correspondence to: Patent Ad		Thibeault, LLP 0 8-7000	Date: January <u>13</u> . Reg. No. 41,418 Tel. No.: (617) 248 Fax No.: (617) 248:	-7240	Patrick R.H. Waller Attorney for Applicant(s)			

OFERSTRANSMITTAL JAN 1 6 2003 2 2003

	Complete if Known	
Application Serial Number	09/514,865	
Filing Date	February 28, 2000	C
First Named Inventor	Shuber	0 1
Group Art Unit	1634	
Examiner Name	S. Sakelaris	
Attorney Docket No.	EXT-036	
		

	NATIVE TO THE PROPERTY OF THE						32
	METHOD OF PA	YMENT			FER	CALCULATION (continued)	2
	ment Enclosed:			3. ADDI	HONAL FI	RES	100
] Check 🔲 Money Ord	er 🔲 Other		Large	Small		7
2 🔯 📆		-,-,-,-		Entity	Entity		•
2. 🛛 The	Commissioner is hereby	authorized to	credit	Fee	Fee	Fee Description	Fee Paid
	charge any fee indicated b		ubmission	(S)	(S)		
10 1	Deposit Account No. 20-0						
	Required Fees (copy o	f this sheet end	closed).	130	65	Surcharge - late filing fee or oath	
	Additional fee required	f under 37 CFI	R 1.16 and	50	25	Surcharge - late provisional filing fee	
	1.17.					or cover sheet	1
	Overpayment Credit.			130	130	Non-linglish specification	-
3. A	pplicant claims small enti-			2,520	2.520	Request for ex parte reexamination	
	FEE CALCULA	TION		110	55	Extension for reply within first month	
1. FILING I	FEE			400	200	Extension for reply within second	
Large Enti	4.					month	
Fee (S)				920	460	Extension for reply within third month	
ree (5)	Fee Description		Fee Paid	1440	720	Extension for reply within fourth	
				1060	090	month	
740	Utility filing fee			1960 320	980 160	Extension for reply within fifth month	
330	Design filing fee		· · · · · · · · · · · · · · · · · · ·	320	160	Notice of Appeal	
160	Provisional filing fee			280	140	Filing a brief in support of an appeal Request for oral hearing	
	••			130	130	Petitions to the Commissioner	
				180	180	Submission of Information Disclosure	180.00
	Number Number	Rate	Amount	1		Statement	180.00
	Filed Extra			740	370	Filing a submission after final	
						rejection (37 CFR 1.129(a))	
Total Claums	- 20 ··	x \$ 18.00 =		740	370		
	2.7	. 3 10.00		/40	.170	For each additional invention to be examined (37 CFR 1.129(b))	
Independent				100	100	Certificate of Correction for	
Claims	- 3 =	x \$ 84.00 =			100	applicant's error	
				Other fee (Spe	ecify)		
☐ Multiple Dep	pendent Claim(s), if any	\$280.00 -		Other fee (Spe	ecity)	· 	
	43.4.4.1.1.123.00000	TOTAL.		ı			
	SMALL ENTITY SUBTOTAL (()	_			
2 AMENDA	MENT CLAIM FEES	1) (3)		1			
Claums		ent Rate	Fee Paid	}			
Remainii			retraid			SUBTOTAL (3) (\$)	180.00
After Ame	•						
							I
Total		x \$ 18.00 =				SUBTOTAL (1)	
Indep.		x \$ 84.00 =				SUBTOTAL (2)	
Claim	entation of Multiple Dep.	+ \$280.00 -				SUBTOTAL (3)	180.00
Ciaiiii	TOTAL		(c)			l	
S	MALL ENTITY DISCOUNT		(\$) (\$)				
	SUBTOTAL (2	_	(\$)0			rom	
		-,	(.8)()			TOTAL (\$)	180.00
	CORRESPONDENCE.	ADDRESS				SIGNATURE BLOCK	
Direct all cor	respondence to:					Respectfully submitted.	
	Patent Adminis				12		J
	l'esta, Hurwitz			Date: January		2 270 2 1 1 1 1 1 2	_]
	High Street To	wer-125 High		Reg. No.: 41,		Patrick R.H. Waller	·
	Boston, MA 0	2110		Tel. No.: (617			
	Tel. No.: (617)			Fax No.: (61)	7) 248-710		
	Fax No.: (617)	248-7100				High Street Tower-125 High	Street
						Boston, MA 02110	1



NT -036 THE CELLER BOOKS PATENT Attorney Docket No. EXT-036

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Shuber

SERIAL NO.:

09/514,865

GROUP NO.:

1634

FILING DATE:

February 28, 2000

EXAMINER:

S. Sakelaris

TITLE:

Methods for Disease Detection

Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

In addition, Applicant notifies the Examiner of the following U.S. patent applications: U.S. Serial No. 09/545,162, filed April 7, 2000; U.S. Serial No. 09/455,950, filed December 7, 1999; U.S. Serial No. 10/149,464, filed June 7, 2002; and U.S. Serial No. 09/724,274, filed November 28, 2000. Furthermore, Applicant notifies the Examiner that U.S. Patent No. 6,084,091 is the English language counterpart of Foreign Patent Document Nos. 195 30 132C2, 195 30 132A1 and WO 97/07239; U.S. Patent No. 6,150,100 is the English language counterpart of Foreign Patent Document No. 197 12 332A1; U.S. Patent No. 6,448,002B1 is the English counterpart of Foreign Patent Document No. WO 98/08971; and an English language abstract for Foreign Patent Document No. 197 36 691A1 is contained in related Foreign Patent Document No. WO 99/10528.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

(1)	within three (3) months of the filing date of a national application other than a
	continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months
	of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an
	international application, or before the mailing of the first Office action on the

01/16/2003 CCHAU1

00000060 09514865

01 FC:1806

180.00 DP

Supplemental Information Disclosure Statement Serial No. 09/514,865 Page 2 of 2

		merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
\boxtimes	(2)	after the period defined in (1) but before the mailing date of a final action or a notice of allowance under 37 C.F.R. 1.311, and
		the requisite Statement is below, OR
	\boxtimes	the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or
	(3)	after the mailing date of a final action or notice of allowance but before the payment of the issue fee, AND
		the requisite Statement is below, AND
		the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein.
	•	fully requested that each of the patents and publications listed on the attached Form

PTO-1449, and other information contained herein, be made of record in this application.

Date: January 13, 2003 Reg. No. 41,418

Tel. No.: (617) 248-7240 Fax No.: (617) 248-7100

2546000_1

Respectfully submitted,

Patrick R. H. Waller, Ph.D. Attorney for Applicant(s)

Testa, Hurwitz, & Thibeault, LLP

High Street Tower 125 High Street

Boston, Massachusetts 02110

SHEET 1 OF 11

U.S. PATENT DOCUMENTS

FORM	м РТС) - 1449			ATTY DOCKET	NO.: EX	⟨Т-036 (2	457/32)
SUPP	SUPPLEMENTAL INFORMATION DISCLOSURES TATEMENT				APPLICANT:		uber	7¢.
DISC!					SERIAL NO.:		/514,865	The Val
	JAN 1	1 6 2003 55			FILING DATE:		bruary 28,	2000 SEA
15		, w 2000 m			GROUP:			Ep,
	A COM	TI MANAY CES		SDATEN	NT DOCUMENTS	163		457/32) PROPERTY OF THE PROPE
EXAM	Ţ	DOCUMENT	DATE	NAME		CLASS	SUB	EII ING BASS -
INIT.		NUMBER				VIA33	CLASS	FILING DATE IF APPROPRIATE
	Λ47	3,413,464	11/26/68	Kamentsk	y			04/29/65
	Λ48	4,101,279	7/18/78	Aslam				4/6/77
	Λ49	4.309.782	1/12/82	Paulin				9/11/80
	Λ50	4,358,535	11/9/82	Falkow et	al.			12/8/90
	Λ51	4,445,235	5/1/84	Slover et c	al.			9/13/82
	A52	4.578,358	3./25/86	Oksman ei	t al.			5/3/83
	A53	4,683,202	7/28/87	Mullis				10/25/85
	A54	4,705,050	11/10/87	Markham				10/2/85
	A55	4,735,905	4/5/88	Parker				8/15/86
	A56	4,935,342	6/19/90	Seligson et	t al.			12/1/86
	A57	5.149,506	9/22/92	Skiba et al	1.			8/9/91
	A58	5.200,314	4/6/93	Urdea				3/23/90
	A59	5,331,973	7/26/94	Fiedler et a	al.			3/15/93
	Λ60	5.416.025	5/16/95	Krepinsky,	et al.			8/31/94
	A61	5,463,782	11/7/95	Carlson et e	al.			11/21/94
	Λ62	5.482.834	1/9/96	Gillespie				1/19/93
	A63	5,506,105	4/9/96	Haydock				3/22/94
	A64	5.538.851	7/23/96	Fach et al.				12/22/93
	A65	5,559,014	9/24/96	Estes et al.				6/7/95
	A66	5.599.662	2/4/97	Respess				2/17/95
	A67	5.612.473	3/18/97	Wu et al.				1/16/96
	Λ68	5.635.352	6/03/97	Urdea et al.				4/26/95
	A69	5.641.628	6/24/97	Bianchi				11/14/94
	A70	5,645,995	7/8/97	Kieback		+		4/12/96

DVA			
EXA:	IVI I	u 🔻	r.K

м рто	- 1449			ATTY DOCKET NO	.: EX	Γ-036 (2457/32)	30
PLEME	NEAL INFORMAT	TION		APPLICANT:	Shu	ber EC	VAN Y
EUSUR	SE STATEMENT			SERIAL NO.:	09/5	514,865	a."
JAN 1	1 6 2003 8			FILING DATE:	Feb	ruary 28, 2000	SA /S
To the same of the				GROUP:	163-	·	1
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	5.688.643	11/18/97	Oka et al			2/27/95	
Λ72	5,846,710	12/8/98	Bajaj			8/6/93	
Α73	5,856,104	1/5/99	Chee et a	ıl.		3/7/97	
A74	5,882,865	03/16/99	Vogelste	in et al.		1/10/97	
A75	5.888,778	3/30/99	Shuber			6/16/97	
A76	5,910,407	6/8/99	Vogelstei	in et al.		8/26/94	
A77	5.916,744	6/29/99	Taylor			3/14/94	
A78	5,942,396	8/24/99	Shiff et a	d.		8/19/97	
A79	5,952,178	9/14/99	Lapidus a	et al.		4/13/98	
A80	5,976,800	11/2/99	Lau et al.			6/27/97	
A81	6,020,137	2/1/00	Lapidus a	et al.		11/23/98	
Λ82	6,037,465	3/14/00	Hillebran	nd et al.		12/16/96	
Λ83	6,100.029	8/8/00	Lapidus e	et al.		12/4/97	
A84	6.143.529	11/7/00	Lapidus e	et al.		3/26/99	
A85	6,146,828	11/14/00	Lapidus			7/3/98	
A86	6.177.251B1	01/23/01	Vogelstei	in et al.		6/8/99	-
A87	6.203,993 B1	3/20/01	Shuber et	t al.		4/4/00	
A88	6,214,187B1	4/10/01	Hammon	d et al.		6/18/99	
A89	6.214,558B1	04/10/01	Shuber et	t al.	Ī	7/27/00	
A90	6.238,927B1	5/29/01	Abrams e	et al.		10/4/99	
A91	6.251,660 B1	6/26/01	Muir et a	et.		11/25/98	
A92	6.268.136B1	7/31/01	Shuber et	t al		11/23/98	
A93	6.280,947 B1	8/28/01	Shuher et	t al		8/11/99	
A94	6,300,077 B1	10/9/01	Shuber et	t al.		4/4/00	
A95	6,303,304 B1	10/16/01	Shuber et	t al.		2/2/99	
A96	6,351.857 B2	3/5/02	Slaon, III	et al.		3/13/01	
A97	6,406,857 B1	6/18/02	Shuber et	t al.		5/21/01	

EXAMINER

DATE CONSIDERED

FORM	PTO	- 1449			ATTY DOCKET NO.: EXT-036 (2457/32) APPLICANT: Shuber Cy Charles Shuber Cy Charles Shuber Cy Charles Serial No.: 09/514.865 FILING DATE: February 28, 2000 600000000000000000000000000000000							
		NTAL INFORMAT	ΓΙΟΝ		APPLICANT	`:	Shuber	ECH AN CIL				
DISCE	DAME	STATEMENT			SERIAL NO.	:	865 CN	8 32				
/	. c 26	103 G			FILING DAT	`E:	February	ک v 28, 2000	7600 103			
MAL. E	163	5			GROUP:		1634	,	1000			
160	DAMA	2.415,455 B1	7/9/02	Slaon, III e	t al.			12/17/	01			
	A99	6,428,964 B1	8/6/02	Shuber				3/15/0	1			
	A100	6,475.738 B2	11/5/02	Shuber et a	ıl.			6/18/0				
	A101	6.482.595 B2	11/19/02	Shuber et a	ıl.			8/27/0	1			
	A102	2001/0018180A1	8/30/01	Shuber et a	ıl.			1/10/0	1			
	A103	2002/0025525 A1	2/28/02	Shuber				5/30/0	t			
	A104	2002/0110810 A1	8/15/02	Shuber				1/5/01				
	A105 2002/0119469 A1 8/29/02 Shubd A106 2002/0119472 A1 8/29/02 Lapid				ıl.			10/5/0	1			
-					set al.			10/15/9	01			
	A107	2002/0132251 A1	2002/0132251 A1 9/19/02 Shu			Shuber			01			
	A108	2002/0164631 A1	11/7/02	Shuber et al.				3/25/00	2			
	A109	6,150,100	11/21/00	11/21/00	Ruschoff et	t al.			3/25/98	3		
_	A110	6,448,002B1	9/10/02	Hillebrand et al.				8//26/9	7			
	A111	6,084,091	7/4/00	7/4/00	7/4/00	7/4/00	Muller et a	1.			8/14/96	
	A112	6,503,718 B2	1/7/03	Shuber et a	1.			1/10/0	I			
			FORE	IGN PATI	ENT DOCU	MENT	S					
EXAM INIT.		DOCUMENT NUMBER	DATE	COUNTR CODE	Y CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N			
	B43	0 270 017A2	6/8/88	EP			11/27/87		Y			
	B44	0 270 017A3	6/8/88	EP			11/27/87		Y			
	B45	0 284 362 A3	9/28/88	EP			3/23/88		Y			
	B46	0 391 565 B1	10/10/90	EP			3/19/90		Y			
B47 195 30 132C2 B48 197 12 332Λ1		195 30 132C2	2/20/97	DE			8/16/95	All1 is English counterpart	N			
		197 12 332Λ1	10/1/98	DE			3/25/97	A109 is English counterpart	N			

EXAMINER			DATE CONSIDERED

FORM PTO	- 1449			ATTY DOCKET NO.:	ЕХТ-03	6 (2457/32) 6 (2457/32) 6 (2457/32) 6 (2457/32) 7 (25) 7 (25) 7 (25) 8 (2457/32)	10°C
SUPPLEME	TAL INFORMA	TION		APPLICANT:	Shuber	16CH	SN S
	ESTATEMENT			SERIAL NO.:	09/514,8	365	Viso 820
JAN 1 6	3003 (G)			FILING DATE:	February	28, 2000	1500
TE STATE OF THE ST				GROUP:	1634		129
B49	197 36 691A1	2/25/99	DE		8/22/97	B111 has English abstract	N
B50	2.327.497Λ	1/27/99	GB	- -	7/15/98		Y
B51	WO 93/20235	10/14/93	PCT		3/31/93		Y
B52	WO 94/00603	1/6/94	PCT		6/28/93		Y
B53	WO 94/01447	1/20/94	PCT		7/1/93		Y
B54	WO 95/00669	1/5/95	PCT		6/22/94		Y
B55	WO 95/12606	5/11/95	PCT		11/5/93		Y
B56	WO 96/23895A	8/8/96	PCT		1/29/96		Y
B57	WO 96/29430A	9/26/96	PCT		3/13/96		Y
B58	WO 97/07239	2/27/97	PCT		8/14/96	A111 is English counterpart	N
B59	WO 97/19191A	5/29/97	PCT		11/15/96		Y
B60	WO 97/28450	8/7/97	PCT		12/20/96		Y
B61	WO 98/08971	3/5/98	PCT		8/26/97	A110 is English counterpart	N
B62	WO 98/39478	9/11/98	PCT		3/2/98		Y
B63	WO 98/58084	12/23/98	PCT		6/16/98		Y
B64	WO 99/07894	2/18,99	PCT		8/5/98		Y
B65	WO 99/07895	2/18/99	PCT		4/8/98		Y
B66	WO 99/20798	4/29/99	PCT		10/22/98		Y
B67	WO 99/26724	6/3/99	PCT		11/25/98		Y
B68	WO 99/28507	6/10/99	PCT		12/3/98		Y
B69	WO 99/45374	9/10/99	PCT		3/3/99		Y
B70	WO 99/53316	10/21/99	PCT		4/13/99		Y
B71	WO 99/55912	11/4/99	PCT		4/23/99		Y

EXAMINER	DATE CONSIDERED

FORM PTO) - 1449			ATTY DOCKET NO.:	EXT-036 (2457/32)	A .
	ENTAL INFORMAT	TION		APPLICANT:	Shuber	PRICK, SOLOWING THE PROPERTY OF THE PROPERTY O
Discroun	RE STATEMENT			SERIAL NO.:	09/514,865	IN K
IAN 1 5 20	m (2)			FILING DATE:	February 28, 2000	12 6
JAN 1 6 ZU				GROUP:	1634	54 CO
I BY	WO 99'66077	12/23/99	PCT	GROOT.	6/16/99	V 50
B73	 	12 23/99	PCT		6/18/99	Y
B74		12/23/99	PCT		6/18/99	Y
B75	 	2/24/00	PCT		8/10/99	Y
B76		3/2/00	PCT		8/10/99	Y
B77	ļ	6/2/00	РСТ		11/17/99	Y
B78		6/2/00	PCT		11/22/99	Y
B79		6/2/00	PCT		11/23/99	Y .
B80	WO 00/32820	6/8/00	PCT		11/23/99	Y
B81	WO 00/50640	8/31/00	PCT		1/24/00	Y
B82	WO 00/50870	8/31/00	PCT		2/25/00	Y
B83	WO 00/58514A3	10/5/00	PCT		3/24/00	Y
B84	WO 00/60118	10/12/00	PCT		3/31/00	Y
B85	WO 00/61808A3	10/19/00	PCT		4/7/00	Y
B86	WO 00/66005	11/9/00	PCT		4/26/00	Y
B87	WO 00/70096	11/23/00	PCT		5/18/00	Y
B88	WO 00/70096 A3	11/23/00	PCT		5/18/00	Y
B89	WO 01/18252A2	3/15/01	PCT		9/8/00	Y
B90	WO 01/42502A2	6/14/01	PCT		9/8/00	Y
B91	WO 01/42503A2	6/14/01	PCT		11/28/00	Y
B92	WO 01/42781A2	6/14/01	PCT		12/7/00	Y
B93	WO 01/64950A2	9/7/01	PCT		2/27/01	Y
1394	WO 01/64950A3	9/7/01	PCT		2/27/01	Y
B95	WO 01/11083 A2	2/15/01	PCT		8/9/00	Y
B96	WO 01/11083 A3	2/15/01	PCT		8/9/00	Y
B97	WO 02/055740 A2	7/18/02	PCT		1/10/02	Y
B98	WO 02/059379 A2	8/1/02	PCT		1/4/02	Y

EXAMINER

DATE CONSIDERED

EXAMIN	NER				DATE CONSIDERED			
	C100				ease II as an Endonucleas I 1, pp. 440-448, January 19		Apoptosis," Arc	hives of
	(.88	the Primer Walking S	trategy of D?	NA Sequer	e Priming Efficiency of Shoncing." <i>DNA Sequence</i> 6:21	1-16.		
	C98	Gastroenterology, Vo	ol. 113, No. 6	o. pp. 1892	esistance to Sulindae-Induc -1900, December 1997.			<u></u>
	C97	Anker et al., (1999), * Cancer and Metastas			ng Tumour DNA in the Blo	od (plasma/s	erum) of Cance	r Patients,"
	C96	Ambrosini et al. "A n Vol. 3, No. 8, pp. 917		-	ie, survivin, expressed in ca	ncer and lyn	nphoma" <i>Natur</i>	e Medicine,
	C95	Allen et al. (1997), "N Toxicol. Methods, Vo			chemical characterization ar 8.	nd analysis o	f apoptosis." <i>J</i> .	Pharm. &
EXAM INIT.		OTHER DOCUMENT	S: (Including	g Author, T	itle, Date, Relevant Pages, P	lace of Public	cation)	
		(THER A	RT, JOU	RNAL ARTICLES, E	TC.		
	B111	WO 99/10528	3/4/99	PCT		8/22/97	Abstract in English	N
	B110	195 30 132A1	2/20/97	DE		8/16/95	AIII is English counterpart	N
	B109	3325270	9/17/02	115		12/20/96	Abstract in English	N
	B108	2.228.769	2/27/97	CA		8/14/96	ļ	Y
	B107	2.211.702	5/25/99	CA		12/20/96		Y
	B106	745862	9/22/98	AU		3/2/98		Y
	B105	744746	1/4/99	AU		6/16/98		Y
	B104	720489	9/30/99	AU		7/28/99		Y
	B103	704696	8/22/97	AU		12/20/96		Y
	B102	711754	7/17:97	AU		12/20/96		Y
	B101	AU199942333 A1	9/30/99	AU		7/28/99		Y
	B100	WO 02/092858 A2	11/21/02	PCT		2/28/02		Y
	B99	WO 02/074995 A1	9/26/02	PCT		3 '15/02		Y
		is de la company			GROUP:	1634	6 (2457) 6 (245 7) 865 7 28, 2000	Reg
JAN	1 6 20	ස දුදු දුදු			FILING DATE:	February	28, 2000	100
	.,,,,,	`\			SERIAL NO.:	09/514,8	365	Co o
.,		TAL INFORMAT ESTATEMENT	ION		APPLICANT:	Shuber	Cy Cx	The C
FORM	11()-	1447		}	ATTY DOCKET NO.:	EA1-03	0 (243)(2)	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\

			~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		
ORM PTO		ATTY DOCKET NO.:	EXT-036 (2457/32) Shuber (2457/32) 09/514,865 February 28, 2000 1634		
UPPLEME ISOLOSUI	NTAL INFORMATION RESTATEMENT	APPLICANT:	Shuber Chy Co.		
	51	SERIAL NO.:	09/514,865		
JAN 162	003 00 j	FILING DATE:	February 28, 2000		
War Comment	A XW CON	GROUP:	1634		
(10)	Bernstein et al. "A Bile Acid-induced Ap Studies." Cancer Research, Vol. 59, pp.	optosis Assay for Colon-Cancel	r Risk and Associated Quality Contro		
C102	Boom et al., (March 1990) "Rapid and Si Vol. 28, No. 3, pp. 495-503.	imple Method for Purification o	f Nucleic Acids" J. Clin. Microbiol ₂ ,		
C103	Croitoru et al. "Reduce, Reuse, and Recycle: Shedding Light on Shedding Cells," <i>Gastroenterology</i> , Vol. 105, pp. 1243-1246, October 1993.				
C104	Cawkwell et al. (1994). "Frequency of allele loss of DCC, p53, RB1, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction." <i>Brit. J. Cam.</i> , Vol. 70, No. 5, pp. 813-818.				
C105	Chen et al., (July 15, 1996), "Detection of Analytical Biochemistry, US, Academic, I	f Single-Base Mutations by a Corress, Vol. 239, No. 1, pp. 61-6	ompetitive Mobility Shift Assay,"		
C106	Coombs et al., (May 21, 1996) "A Rapid, Stool Samples," ASM 1996 General Meet	Simple, and User-Friendly Met	hod for DNA Extraction from Clinica		
C107	Dennin, (1979), "DNA of Free and Comp Distribution," Klin. Wochenschr, Vol. 57,	lexed Origin in Human Plasma: pp. 451-456.	Concentration and Length		
C108	Depraetere, " 'Eat me' Signals of apoptoti	ic bodies," Nature Cell Biology,	Vol. 2, pg. E104, June 2000.		
C109	Ditkoff et al. (1996), "Detection of circula 959-65.	iting thyroid cells in peripheral l	blood." Surgery Vol. 120, No. 6, pp		
C110	Eads et al., (1999) "CpG Island Hypermet Methyltransferase Overexpression." Cance	hylation in Human Colorectal T er Research, Vol. 59, No. 10, pp	tumors Is Not Associated with DNA p 2302-2306.		
CHI	Echeverria et al., (September 1985) "DNA Laboratory Medicine, Vol. 5, No. 3, Septe	Hybridization in the Diagnosis ember 1985, pp. 447-462.	of Bacterial Diarrhea." Clinics in		
C112	Emlen et al., (1984), "Effect of DNA Size DNA," Clin. exp. Immunol, Vol. 56, pp. 13	and Strandedness on the <i>in vivo</i> 85-192.	Clearance and Organ Localization o		
C113	Finkel "Does Cancer Therapy Trigger Cell	Suicide?," Science, Vol. 286, p	pp.2256-2258. December 17, 1999.		
C114	Fournie et al., (1995), "Plasma DNA as a I from Lung Cancer and in Nude Mice Bear	Marker of Cancerous Cell Death ing Human Tumours," Cancer L	n. Investigations in Patients Suffering Letters, Vol. 91, pp. 221-227.		
C115	Garewal et al. "Reduced Bile Acid-induced Marker for Cancer Risk" Cancer Research	d Apoptosis in 'Normal' Colore , Vol. 56, pp. 1480-1483, April	ctal Mucosa: A Potential Biological 1, 1996.		
C116	Giacona, et al. (1998). "Cell-free DNA in I Pancreatic Cancer and Healthy Controls."	Human Blood plasma: Length N Pancreas, Vol. 17, No. 1, pp. 89	deasurements in Patients with 9-97.		
C117	Halim, "Apoptosis: "Orderly Dismantling"	The Scientist, pg. 19, February	7, 2000.		

EXAMINER	DATE CONSIDERED

SHEET 8 20 11

FORM PTO	- 1449	ATTY DOCKET NO.:	EXT-036 (245 (32)	
	NTAL INFORMATION	APPLICANT:	Shuber	
iaci nasi	STATEMENT	SERIAL NO.:	09:514,865	
IS B L MAI	( <del>)</del> (2)	FILING DATE:	EXT-036 (245 (22)	
3 - 5g		GROUP:	1634	
CITY	Hall et al. "Regulation of cell number in the <i>Journal of Cell Science</i> , Vol. 107, pp. 356		tract: the importance of apoptosis,"	
C119	Hetts, "To Die or Not to Die, An Overview 300-307, January 28, 1998.	of Apoptosis and Its Role in	Disease," <i>JAMA</i> , Vol. 279, No. 4, pp.	
C120	Hibi et al., (April 1998), "Molecular Detec Patients," Cancer Research, Vol. 58, pp. 1-		the Serum of Colorectal Cancer	
C121	Hitchcock, "Actin-Deoxyribonuclease I Interaction," <i>The Journal of Biochemical Chemistry</i> , Vol. 255, No. 12, pp. 5668-5673, 1980.			
C122	Hunsaker, et al. (1989), "Use of Reversible Target Capture to Detect Subattomole Quantities of Target Nonradioleotopically in Crude Specimens in One Hour," Abstracts of the 89th Meeting of the American Society for Microbiology, D-169, Pg. 110.			
C123	Ito et al., (1999), "Profile of Circulating Levels of Interleukin-1 Receptor Antagonist and Interleukin-6 in Colorectal Cancer Patients," Scand. J. Gastroenterol., Vol. 11, pp. 1139-1143.			
C124	Iwanaga et al. "A Novel Mechanism for Di Pigs," <i>Gastroenterology</i> , Vol. 105, No. 4, p	-	ells in the Small Intestine of Guinea	
C125	Kataoka et al. "Association of high molecule death induced by calcium ionophore" FEBS			
C126	Kawasaki et al. "Inhibition of Apoptosis by Cancer Research, Vol. 58, pp. 5071-5074.		rvival Rates in Colorectal Cancer,"	
C127	Kishi et al. "Human Serum Deoxyribonucl from Serum, Urine, Kidney, Liver, and Pan			
C128	Komano et al. "Homeostatic regulation of it USA 92, Vol. 92, pp. 6147-6151, June 1995		helial γδ T cells" Proc. Natl. Acad. Sci.	
C129	Lefrere et al., (October 1998)"Screening Bl Simulation Using Pooled Samples on the X			
C130	Leon et al., (March 1977), "Free DNA in the Research, Vol. 37, pp. 646-650.	ne Serum of Cancer Patients a	nd the Effect of Therapy," Cancer	
C131	Li et al., (August 1996) "Rapid Detection o Immunomagnetic PCR," J. Clin. Microbio			
C132	Lipkin, "Biomarkers of Increased Susceptib Prevention in Human Subjects," Cancer Re	-	* *	
C133	Maebo, (1990), "Plasma DNA Level as a Tattached.	umor Marker in Primary Lung	2 Cancer." Japanese: English abstract	

EXAMINER	DATE CONSIDERED

FORM PTO	- 1449	ATTY DOCKET NO.:	EXT-036 (2457/32)		
	NTALINFORMATION	APPLICANT:	Shuber FOX AN		
	E STATEMENT	SERIAL NO.:	09/514.865		
i MAI	6 7003 5	FILING DATE:	EXT-036 (2457/32)  Shuber C. A. O.		
5. 5. co.	HI MARIN COLO	GROUP:	1634		
C134		DNAase I Complex Formed by ecember 1975.	the Action of DNAase I on F-Actin,"		
C135	Mannherz et al. "The Interaction of Bovine <i>Biochem</i> , Vol. 104, pp. 367-379, 1980.	Pancreatic Deoxyribonucleas	se I and Skeletal Muscle Actin" Eur. J.		
C136	Metspalu A., "Arrayed Primer Extension (APEX) for Mutation Detection Using Gene-Specific DNA Chips" European Society of Human Genetics, Vol. 6, No. Sup 1, 1998, page PL36 XP000892253 Abstract.				
C137	Morandi et al., (June 1998) "Detection of HIV Type 1 RNA in Pools of Sera Negative for Antiobiotics to HIV-1 and HIV-2," J. of Clinical Microbiology, Vol. 36, No. 6, pages 1534-1538.				
C138	Morrissey et al., (May 14-18, 1989) "Nove Specimens" American Society for Microbia				
C139	Morrissey, et al., (September 1989) "Nucle Analytical Biochemistry, Vol. 181, No. 2, p		Employing dA-Tailed Capture Probes.		
C140	Morrissey, D. and Collins, M., (June 1989) Probes. Single Capture Methods," Mol. Ar				
C141	Mulcahy et al. (1998), "A prospective study Cancer Res., Vol. 4, pp 271-75.	of K-ras mutations in the pla	isma of pancreatic cancer patients." Clin		
C142	Olive, (February 1989) "Detection of Enter Amplification with a Thermostable DNA Po 261-265.				
C143	Paabo <i>et al.</i> . (1988) "Mitochondrial DNA S 16, No. 20, pp. 9775-9787.	Sequences from a 7000-year o	ld Brain," <i>Nucleic Acids Research</i> , Vol		
C144	Pacek et al., (May 1993)"Determination of Analysis of DNA Amplified from Pooled Sa				
C145	Park et al. "Detergent and Enzyme Treatme BioTechniques, Vol. 24, No. 4, pp. 558-559	• •	ervation of DNA Fragmentation``		
C146	Payne et al. "Role of Apoptosis in Biology Ultrastructural Pathology, Vol. 19, pp. 221		Apoptosis in Colon Carcinogenesis"		
C147	Pertisch et al. "Characterization of the endog during apoptosis (programmed cell death)."				
C148	Peitsch et al. "Functional characterisation o Communications, Vol. 186, No. 2, pp. 739-		ochemical and Biophysical Research		
C149	Peitsch et al. "The apoptosis endonucleases 37-41, February 4, 1994.	: cleaning up after cell death?	," Trends in Cell Biology, Vol. 4, pp.		

ı			
1	EXAMINER	DATE CONSIDERED	l

CODM DTO 1440		——————————————————————————————————————			
FORM PTO - 1449	ATTY DOCKET NO.:	EXT-036 (2457/32)			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	APPLICANT:	EXT-036 (2457/32)  Shuber  09/514,865  February 28, 2000			
JAN 1 6 2003 (2)	SERIAL NO.:				
JAN 1 0 2000 A.	FILING DATE:	February 28, 2000			
SAIN MACH	GROUP:	1634			
C150 Polzar et al. "Distribution of deoxyrib apoptosis (programmed cell death)," /	onuclease I in rat tissues and its of European Journal of Cell Biology	correlation to cellular turnover and c. Vol. 64, pp. 200-210, 1994.			
C151 Polzar et al. "Overexpression of deoxy apoptotic cell death." European Journ	Polzar et al. "Overexpression of deoxyribonuclease I (DNase I) transfected into COS-cells: its distribution d apoptotic cell death." <i>European Journal of Cell Biology</i> , Vol. 62, pp. 397-405, 1993.				
C152 Raptis <i>et al.</i> , (December 1980), "Quan Systemic Lupus Erythematosus," <i>J. CI</i>	Raptis <i>et al.</i> , (December 1980), "Quantitation and Characterization of Plasma DNA in Normals and Patients wit Systemic Lupus Erythematosus," <i>J. Clin. Invest.</i> , Vol. 66, pp. 1391-1399.				
C153 Rinaldy et al. (1988), "Gene Cloning U Strategy: Application to Cloning XP	Rinaldy <i>et al.</i> (1988). "Gene Cloning Using cDNA Libraries in a Differential Competition Hybridization Strategy: Application to Cloning XP-A Related Genes." <i>DNA</i> Vol. 7, No. 8, pp. 563-70.				
C154 Ruzicka et al., (1992) "Apolipoprotein of Lipid Research, Vol. 33, pp. 1563-1	Ruzicka et al., (1992) "Apolipoprotein Allele Specific PCR: Large-Scale Screening of Pooled Blood Samples," . of Lipid Research, Vol. 33, pp. 1563-1567.				
C155 Saitoh et al. "Analysis of Bel-2, Bax ar Vol. 15, pp. 137-141, 1999.	nd Survivin genes in uterine canc	eer". International Journal of Oncology,			
C156 Sales et al., (July 31, 1999), "Blood D Rectosigmoid Cancer," The Lancet, Vo	issemination of Colonic Epithelia ol. 354, p. 392.	nl Cells During No-touch Surgery for			
C157 Samiotaki et al. (1994), "Dual-Color D Genomics 20:238-42.	Detection of DNA Sequence Varia	ants by Ligase-Mediated Analysis,"			
C158 Schmitt et al. (1998), "Bax-alpha pronactivation of caspase 3-like cysteine produiff., Vol. 5, No. 6, pp 506-16.	motes apoptosis induced by canceroteases in p53 double mutatnt B	er chemotherapy and accelrates the lymphoma Namalwa cells." Cell Death &			
C159 Sen "Programmed Cell Death: Concept	t. Mechanism and Control" Biol.	Rev., Vol. 67, pp. 287-319, 1992.			
C160 Shapiro et al., (June 1, 1983), "Determ Gastrointestinal Disease" Cancer, Vol.	ination of Circulating DNA Leve 51, No. 11, pp. 2116-2120.	els in Patients with Benign or Malignant			
C161 Shaw et al., (1998) "Allele Frequency I Disease Genes," Genome Research, Vo	Distribution in Pooled DNA Samol. 8, pp. 111-123.	ples. Applications to Mapping Complex			
C162 Sidransky, D. (1997) "Nucleic acid-bas 1054-1058.	sed methods for the detection of c	rancer." Science, Vol. 278, No. 5340, pp.			
C163 Skoletsky et al. (1998) "High frequency individuals." Gastroenterology, Vol. 1		n stools of apparently normal			
C164 Sträter et al. "Rapid Onset of Apoptosis Colonie Crypt Cell" <i>Gastroenterology</i> .	s In Vitro Follows Disruption of Vol. 110, No. 6, pp. 1776-1784,	B1 Integrin/Matrix Interactions in Human June 1996.			
C165 Stroun et al., (1987), "Isolation and Ch	Stroun <i>et al.</i> , (1987), "Isolation and Characterization of DNA from the Plasma of Cancer Patients," <i>Eur. J. Cancer Clin. Oncol.</i> , Vol. 23, No. 6, pp. 707-712.				
Cancer Clin. Oncol., Vol. 23, No. 6, pp.	5. /0/-/12.				

EXAN	IINER	
------	-------	--

SHEET 11 OF 11

			· //	
FORM PTO	- 1449	ATTY DOCKET NO.:	EXT-036 (2457,32) Shuber  09/514.865 February 28, 2000	
SUPPLEMENTAL INFORMATION		APPLICANT:	Shuber Cy AN	
,	ESTATEMENT	SERIAL NO.:	09/514.865	
IAN 1 6 2003 &)		FILING DATE:	February 28, 2000	
	OTH COLUMN	GROUP:	1634	
टील	Tsujitani et al. "Apoptotic Cell Death and l Supplement, Vol. 77, No. 8, pp. 1711-1716		nesis in Colorectal Carcinoma," Cancer	
C168	Vera-Garcia, et al., (May 16-20 1993) "Development and Evaluation of an Instrument Designed to Reproducibly Release Nucleic Acids from Microorganisms" American Society for Microbiology: Polymerase Chain Reaction, 93 rd General Meeting, Session 214, Abstract C-217, p. 484.			
C169	Vet et al., (1998) "Comparative analysis of Clin. Path., Vol. 110, No. 5, pp. 647-652.	p53 mutations in bladder wa	shings and histologic specimens" Am. J.	
C170	Vogelstein <i>et al.</i> , (1979) "Preparative and Analytical Purification of DNA from Agarose," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 76, No. 2, pp. 615-619.			
C171	Wagner et al. "Regulation of Gastric Epithelial Cell Growth by Helicobacter pylori: Evidence for a Major Role of Apoptosis," <i>Gastroenterology</i> , Vol. 113, No. 6, pp. 1836-1847, December 1997.			
	Walsh <i>et al.</i> , (1991) "Chelex K 100 as a Medium for Simple Extraction of DNA for PCR-Based Typing from Forensic Material," <i>BioTechniques</i> , Vol. 10, No. 4, pp. 506-513.			
C172			DIDNA for PCR-Based Typing from	
C172		0, No. 4, pp. 506-513.	· · ·	

2545288 1